Italian CRO, LB Research, Joins the 1MED Group

1MED today announces that LB Research is now part of the 1MED Group. Established in 2007 and based in Como, Italy, LB Research is a full-service contract research organisation providing clinical trial management across all clinical product life cycle phases.

LB Research operates with a highly skilled team of 24 professionals and maintains a diverse client portfolio, including well established global and Italian pharmaceutical companies. The addition of LB’s expertise will enhance 1MED’s clinical service offerings for pharmaceutical and medical device trials alike.

With extensive experience in clinical trial management across a variety of therapeutic areas, LB Research has developed a particularly strong track record in Oncology studies, providing complementary expertise to 1MED’s capabilities.

This integration marks a strategic step forward in expanding 1MED’s clinical operations and strengthening its foothold in the European pharmaceutical and medical device markets.

Andrea Biffi, Chair of 1MED commented: “The addition of LB Research further enhances 1MED’s reputation as a trusted partner for the medtech and pharma community, advancing and promoting innovations, and improving patient outcomes globally.

It will provide us with an even stronger footprint in Italy and Southern Europe and reinforce some of the therapeutic areas we already operate in (cardiovascular / dermatology) while expanding our oncology capabilities.”

Flavio Lietti, Founder of LB Research said: “LB is excited to become part of the 1MED Group and looks forward to expanding its high-quality international solutions for clients in the medtech and pharma industry.”

Anne-Laure Meynier, Partner at Apposite Capital, added: “The addition of LB to the 1MED family is a significant move for us that in particular strengthens our clinical CRO services throughout Europe, further adding customizable solutions to the 1Med offering.”

Advising 1MED and Apposite on the transaction were Lexsential (legal) and Mazars (financial and tax).

Advising LB Research on the transaction were Marco Polo Advisor (corporate finance) and BLF Studio Legale (legal).

21.11.2024

Back to news